Competition
Competition — Onyx Biotec Limited
Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.
Onyx holds a commodity position, not a moat. It sells the same FFS sterile-water ampoule and cephalosporin vial that ~1,000 unlisted Solan and Baddi WHO-GMP SMEs sell, and that Innova Captab — a listed peer in the same Himachal Pradesh manufacturing belt — sells at 25× the scale. Schedule M is the one real tailwind, but it raises Onyx's own capex bar even as it thins the unlisted SME tail. The single competitor that matters most is Innova Captab (INNOVACAP): same state, same cephalosporin block, same B2B brand-owner customer base, but at $169M revenue with 15% ROCE.
Bottom line on the moat. No switching cost, no regulatory asymmetry (WHO-GMP only; no EU-GMP / USFDA), no scale, no specialty IP. The 14-year customer relationships read like loyalty but are actually one-purchase-order deep — every top-10 customer is a multi-billion-dollar brand-owner that can move volume in 60-90 days. Treat Onyx's competitive position as a price-taker on Layer-2 conversion, and price the equity accordingly.
The Right Peer Set
The five listed comparators below are not arbitrary. JBCHEPHARM and COHANCE are explicitly named in Onyx's IPO RHP "Basis for Issue Price" chapter as the only two listed peers — that pins the upper valuation envelope. AKUMS is the largest Indian-focused pure-play CDMO (1,400+ clients across 60 dosage forms) and is the structural template Onyx would have to evolve toward. INNOVACAP is the closest like-for-like: same Himachal Pradesh manufacturing belt (Baddi, ~30 km from Solan), same cephalosporin block, same B2B-to-Indian-pharma model, but ten years more mature. SENORES is the closest product-line peer (specialty injectables CMO out of Chhatral, Gujarat) and benchmarks the SME→mainboard IPO runway Onyx aspires to. Concord Biotech was Dan-staged but excluded as a fermentation-API CMO that competes for a different contract pool.
The scale gap is the dominant fact in this table. Onyx prints $7M of revenue against an Indian CDMO peer median of $235M — roughly 1/30th of the peer median, and 1/62nd of Akums. The valuation gap is consistent with the operating-quality gap: P/B 1.05x vs peer median ~4.6x, ROCE 1.1% vs peer median 15.0%. Two of the five peers (JBCHEPHARM, COHANCE) are RHP-cited; two (AKUMS, INNOVACAP) are the strongest economic substitutes on business-model overlap; one (SENORES) is the closest product-line peer for cephalosporin DPI and benchmarks the SME→mainboard re-rating pathway.
Onyx is the bottom-left dot — under 5% OPM and ~1% ROCE — and not because the peer set is forgiving. Every other listed peer in this chart clears 10% OPM and 8% ROCE. The thing this chart hides is the dispersion within the peer set: Senores and JB Chem print 27% OPM on very different stories (specialty injectables + own-brand vs branded formulations + CMO); Innova Captab is the closest read of what a "pure-play CDMO that did the work" looks like when it cleared Onyx's hurdle at scale.
Where The Company Wins
There are exactly three places Onyx still has a defensible position vs the listed peer set — none of them are durable moats, but all three are real enough to factor into the next 24 months.
The honest read of this table is that advantages 3 and 4 are weak — installed-base inertia at the SME end of the market is real but not priced, and a simpler compliance footprint is the consequence of being small, not a competitive choice. Advantage 1 (FFS line unit-cost) is the only genuine micro-edge, and it operates inside a commoditised end-market where a fraction of a cent per ampoule moves customer share. Advantage 2 (Schedule M readiness) is the most monetisable, because it converts a regulatory-headwind for unlisted competitors into displaced volume that compliant CDMOs can absorb — but Innova, Akums and others are also compliant, so Onyx will share the displaced pool with the same listed peers it can't outcompete on the rest.
Where Competitors Are Better
The competitive deficit is much larger than the competitive advantage. Four gaps stand out, each tied to a specific listed peer to make the comparison concrete.
Competitive scorecard — 1 (weakest) to 5 (strongest), grouped by dimension then ticker order.
The heatmap reads the same way the table does: Onyx is the weakest column on every single dimension. The closest competitor on absolute scale (SENORES) is at 9× Onyx revenue and 85× Onyx market cap. The closest on business mix (INNOVACAP) is at 23× revenue and 87× market cap and is already in the next state over. There is no dimension on which Onyx is structurally ahead of any listed peer.
Threat Map
The threat catalogue below sorts by what is most likely to take share or compress margin in the next 24 months — not by sensationalism. The single non-listed threat (the unlisted Solan/Baddi SME tail) is rated High because Schedule M is the only event that can either eliminate it or accelerate it; the timing is binary.
The three High-severity threats share one structural property: each one operates inside the customer relationship that Onyx already has, not outside it. A brand-owner that runs its own lines (threat #2) decides every quarter how much volume to outsource. An unlisted Solan competitor (threat #3) sits 30 kilometres away and quotes the same ampoule for fractionally less. Innova Captab (threat #1) is the same brand-owner's preferred vendor for the regulated-market portion of the cephalosporin volume Onyx is trying to win in Unit II. The Medium threats are slower; the Low threats are valuation-shape rather than share-take.
Moat Watchpoints
There are five measurable signals that tell an investor whether Onyx's competitive position is improving or eroding. Each is observable in a routine NSE filing, half-yearly result, or industry data point — none require speculation.
The competitive judgement, condensed. Onyx is a price-taker in a commoditised conversion-layer segment, ringed by listed peers with structural advantages on every dimension (scale, regulatory breadth, customer diversification, margin profile, capital efficiency) and by hundreds of unlisted SMEs competing on price at the SWFI end. The competitive question that matters in the next two years is whether Innova Captab's Kathua ramp pulls cephalosporin volume away from Onyx's Unit II faster than Schedule M closures push SWFI volume toward Onyx's Unit I. Neither outcome supports a moat-compounder narrative; both are consistent with a book-value name where the optionality is real but the asymmetry is not.